Evgen Pharma (EVG) Share Price, News & Analysis

Company Overview

Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: 0.80 to 0.80
• 52-Week Range: N/A
• Volume: 227,410 shs
• Average Volume: 1.73 million shs
• Market Capitalization: £3.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EVG Stock Analysis - Frequently Asked Questions

How were Evgen Pharma's earnings last quarter?

Evgen Pharma plc (LON:EVG) announced its quarterly earnings data on Monday, June, 15th. The company reported ($2.10) earnings per share for the quarter, meeting analysts' consensus estimates of ($2.10).

How do I buy shares of Evgen Pharma?

Shares of EVG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Evgen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evgen Pharma investors own include genedrive (GDR), Motif Bio (MTFB), B&M European Value Retail (BME), Capital & Counties Properties PLC (CAPC), Coats Group (COA), 4D pharma (DDDD) and Greencore Group (GNC).

Company Calendar

• Last Earnings: 6/15/2020
• Today: 7/14/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Financial Services
• Current Symbol: LON:EVG
• CIK: N/A
• Web: evgen.com
• Phone: +44-151-7053532
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£3.35 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -60.57%
• Return on Assets: -45.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.39
• Quick Ratio: 23.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: 1.71
• Book Value: GBX 1 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 427,350,000
• Free Float: N/A
• Market Cap: £3.42 million
• Optionable: Not Optionable
• Beta: 1.44